Q2 2025 · 13F-HR
First Light Asset Management, LLCholdings as filed
Filed 2025-08-14 · accession 0001999371-25-011375
$771.3M
Reported value
38
Positions
2025-06-30
Period end
The Brief · First Light Asset Management, LLC · Q2 2025
AI · grounded in 13F
First Light Asset Management, LLC established a new position in ANAB valued at $78.6M. The fund also initiated new stakes in CNTA for $56.4M and PFMTUSD for $52.7M. Additional new positions include NEO, AXGN, and HCAT. The fund ended the period with 38 positions and total AUM of $771.3M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 032724106 | ANAB | ANAPTYS BIO INC | $78.6M | 10.2% | 3,539,593 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS LIMITED | $56.4M | 7.31% | 4,293,411 | Common | SOLE |
| 71377E105 | PFMTUSD | PERFORMANT HEALTHCARE INC | $52.7M | 6.83% | 13,170,381 | Common | SOLE |
| 64049M209 | NEO | NEOGENOMICS INC | $50.0M | 6.49% | 6,846,432 | Common | SOLE |
| 05463X106 | AXGN | AXOGEN INC | $49.1M | 6.37% | 4,529,243 | Common | SOLE |
| 42225T107 | HCAT | HEALTH CATALYST INC | $46.1M | 5.98% | 12,230,181 | Common | SOLE |
| 90184D100 | TWST | TWIST BIOSCIENCE CORPORATION | $34.8M | 4.51% | 945,033 | Common | SOLE |
| 04963C209 | ATRC | ATRICURE INC | $33.3M | 4.31% | 1,015,170 | Common | SOLE |
| 825704109 | SIBN | SI-BONE INC | $33.0M | 4.27% | 1,751,001 | Common | SOLE |
| 450056106 | IRTC | IRHYTHM TECHNOLOGIES | $28.8M | 3.74% | 187,355 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS INC | $24.9M | 3.22% | 864,136 | Common | SOLE |
| 68621F102 | ORGO | ORGANOGENESIS HOLDINGS INC | $24.8M | 3.22% | 6,777,163 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $22.5M | 2.91% | 1,714,019 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL INC | $19.9M | 2.58% | 547,905 | Common | SOLE |
| G31249108 | ESTA | ESTABLISHMENT LABS HOLDINGS | $17.8M | 2.31% | 417,157 | Common | SOLE |
| 000899104 | ADMA | ADMA BIOLOGICS INC | $17.3M | 2.25% | 952,096 | Common | SOLE |
| 81727U105 | SENS1GBP | SENSEONICS HOLDINGS INC | $17.0M | 2.21% | 35,708,124 | Common | SOLE |
| 759910102 | KRMD | KORU MEDICAL SYSTEMS INC | $16.8M | 2.17% | 4,681,626 | Common | SOLE |
| 641288105 | NPCE | NEUROPACE INC | $15.4M | 1.99% | 1,380,410 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $13.3M | 1.72% | 562,981 | Common | SOLE |
| 602496101 | MDXG | MIMEDX GROUP INC | $11.8M | 1.53% | 1,927,494 | Common | SOLE |
| 142152107 | CAI | CARIS LIFE SCIENCES INC | $11.2M | 1.46% | 443,043 | Common | SOLE |
| 124155102 | BFLY | BUTTERFLY NETWORK INC | $10.9M | 1.42% | 5,465,032 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $8.8M | 1.14% | 180,615 | Common | SOLE |
| 30050B101 | EVH | EVOLENT HEALTH INC | $8.3M | 1.08% | 738,550 | Common | SOLE |
| 65443P102 | MASS | 908 DEVICES INC | $7.6M | 0.99% | 1,067,613 | Common | SOLE |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $7.0M | 0.91% | 2,600,498 | Common | SOLE |
| 40131M109 | GH | GUARDANT HEALTH | $6.7M | 0.87% | 128,868 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $6.3M | 0.82% | 62,901 | Common | SOLE |
| 829214105 | SLP | SIMULATIONS PLUS INC | $6.2M | 0.81% | 357,157 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS | $5.9M | 0.76% | 188,367 | Common | SOLE |
| 759916109 | RGEN | REPLIGEN CORP | $5.5M | 0.71% | 43,949 | Common | SOLE |
| 01625V104 | ALHC | ALIGNMENT HEALTHCARE INC | $5.4M | 0.70% | 383,663 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $4.8M | 0.62% | 520,631 | Common | SOLE |
| 750491102 | RDNT | RADNET INC | $3.9M | 0.51% | 68,694 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $3.5M | 0.45% | 149,596 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $2.5M | 0.33% | 122,226 | Common | SOLE |
| 516544103 | LNTH | LANTHEUS HOLDINGS INC | $2.5M | 0.32% | 30,045 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.